Abstract
Background:
Gorham-Stout disease (GSD) is a rare osteolytic disease with unknown etiology, varied clinical manifestations and unpredictable prognosis. This disease is characterized by progressive massive local osteolysis and resorption caused by intraosseous lymphatic vessel structure and thin-walled vascular proliferation. The diagnosis of GSD has not yet formed a uniform standard, but the combination of clinical manifestations, radiological features and unique histopathological examinations and excluding other diseases contribute to early diagnosis. Although medical therapy, radiotherapy and surgical interventions or combinations have been used for the treatment of GSD, there is currently still no recommended standardized treatment regimen.
Case report:
This paper presents a case of a previously healthy 70-year-old man presented with a 10-year history of severe right hip pain and progressive walking disorder of the lower limbs. Based on the patient's clear clinical presentation, unique radiological features, and histological findings, a diagnosis of GSD was made with the exclusion of other potential diseases. The patient was treated with bisphosphonates to slow the progression of the disease followed by total hip arthroplasty to help restore walking function. At the 3-year follow-up, the patient returned to normal walking and no recurrence was observed.
Conclusion:
Bisphosphonates combined with total hip arthroplasty may be an effective method for the treatment of severe GSD in the hip joint.
Introduction
Gorham-Stout disease (GSD), also termed idiopathic massive osteolysis, vanishing bone disease, phantom bone disease, acute spontaneous absorption of bone, and Gorham disease, is an exceedingly rare osteolytic disease characterized by progressive massive local osteolysis and resorption caused by spontaneous intraosseous lymphatic vessel structure and thin-walled vascular proliferation (–). At present, approximately 400 cases have been reported in the literature. Due to the low incidence and high misdiagnosis rate of GSD, the cases reported in the literature are case reports and small sample series cases (). Although some researchers have conducted the cytology and molecular studies, the etiology and pathogenesis of GSD are still unclear (, ). The incidence of GSD does not differ significantly among genders, ages, regions, or ethnicities, although most cases occur in children as young as 1 month old and young adults under 40 years old (, ). In elderly patients, it often predicts a poor prognosis.
In most cases, GSD usually occurs in a single bone, and in a few cases, it occurs in multiple bones. GSD occurs in a wide range of bones and has been reported to involve the femur, ribs, jaw, humerus, tibia, fibula, and spine (–). The clinical symptoms of GSD are diverse, depending on the lesion accumulation and the rate of disease progression. A small number of patients are asymptomatic, and most cases show unspecific symptoms such as pain, swelling, and dysfunction in the affected bones (–). The incidence of chylothorax caused by GSD is as high as 17%, and the mortality rate is as high as 34% (–). When the cervical spine is involved, it can show spinal cord compression and neurological deficits ().
Laboratory examinations, radiological examinations and histopathological examinations are crucial for the diagnosis of GSD. Laboratory blood tests can provide evidence to rule out infections, myeloma, hyperparathyroidism, and other diseases, but they are less specific for diagnosis (, ). Osteolysis is the most prominent feature of GSD on radiological examinations, which include radiography, computed tomography (CT) scan, magnetic resonance imaging (MRI), emission computed tomography (ECT), and positron emission tomography (PET)/CT (). Pathological examination is the gold standard for the diagnosis of GSD (, ). In 1963, Heffez et al. () proposed 8 diagnostic criteria for Gorham-Stout disease, which can provide references for the diagnosis (Table 1). The treatment of GSD includes medical therapy, radiotherapy and surgical intervention or combination therapy (, ). In this report, we studied a case of GSD in the right hip joint that was treated with bisphosphonates followed by a total hip arthroplasty.
Table 1
| Criteria | Conformity | |
|---|---|---|
| 1 | Positive biopsy findings in terms of angiomatous tissue | ✓ |
| 2 | Absence of cellular atypia | ✓ |
| 3 | Minimal or no osteoclastic response and absence of dystrophic calcifications | ✓ |
| 4 | Evidence of local bone progressive resorption | ✓ |
| 5 | Non-expansive lesion | NA |
| 6 | Absence of visceral involvement | ✓ |
| 7 | Osteolytic radiographic pattern | ✓ |
| 8 | Negative hereditary, metabolic, neoplastic, immunologic, and infectious etiology | ✓ |
Eight criteria proposed by heffez et al. () for the diagnosis of Gorham-Stout disease.
NA, Not available.
Case report
A 70-year-old man presented with a 10-year history of severe right hip pain and a 2-month history of progressive walking disorder of the lower limbs. The patient was previously treated with nonsteroidal anti-inflammatory drugs elsewhere due to pain, but the pain relief was not significant until the patient was unable to walk and was admitted to the emergency department of our hospital in May 2018. The patient had no history of alcoholism, hormone use, or trauma. Initial physical examination revealed positive tenderness in the right groin, positive patrick's sign, and rotation and abduction significantly less than the left hip joint. No redness or skin temperature increase was observed in the right hip joint.
Preliminary anteroposterior (Figure 1A) and lateral (Figure 1B) radiograph examinations of the right hip joint indicated that the femoral head had disappeared and that the margins of the femoral neck and acetabulum were incomplete, which were further confirmed by 3D reconstruction images (Figure 1C) and CT scan images (Figures 1D,E). In particular, the 3D reconstruction and CT scan images clearly demonstrated the range of local osteolysis involving the acetabulum and femoral neck. MRI images (Figures 1F–I) showed hypointensity on T1-weighted images, extensive hyperintensity on fat-suppressed T2-weighted images, and massive joint effusion in the right hip joint. To further clarify the progression of the disease, ECT examination (Figure 2) was performed and the results showed increased focal concentrations of radiotracers in the right femoral head, femoral neck, and acetabulum. Therefore, we highly suspected that this patient may be diagnosed with a malignant bone tumor with aggressive osteolytic lesions. In addition, the chest radiograph was normal, and no obvious signs of tuberculosis were found. Laboratory blood tests showed normal levels of leukocytes, neutrophil granulocyte ratio, hypersensitive C-reactive protein, erythrocyte sedimentation rate, serum calcium, phosphorous, alkaline phosphatase, and parathyroid hormone. Oncology indicators such as alpha fetoprotein, carcinoembryonic antigen and PSA were all within the normal range. The T-SPOT test was negative. To further clarify the diagnosis, an open biopsy of the right hip joint was performed under general anesthesia. A total of 6 cm3 tissues were obtained from the right femoral neck, synovial membrane, and acetabulum. Subsequent histological examinations showed that the necrotic bone tissue was accompanied by focal aggregation of osteoclasts, giant cells and plasma cells without cellular atypia, some proliferative thin-walled capillaries and lymphatic structures, and replaced by fibrous connective tissue (Figure 3). Combined with clinical manifestations, laboratory blood tests, radiological features and histopathology examinations, the patient met seven out of the eight diagnostic criteria for GSD proposed by Heffez et al. () (Table 1). Eventually, the patient was diagnosed with GSD. The patient was then treated with medication, including bisphosphonates (4 mg/week, iv), vitamin D (600 UI/day), and calcium (600 mg/day) for one month. The surgical criteria for total hip replacement in patients with GSD were considered as follows: (i) the patient was 70 years old; (ii) The GSD lesions had involved the acetabulum and the neck of the femur, and in a serious case, the femoral head had completely disappeared. (iii) Contraindications to surgery have been ruled out by relevant examinations. (iii) The patient has a strong need to restore lower limb motor function. We first completely removed the GSD-accumulated bone with the assistance of intraoperative pathologic examination, and then fitted a total hip arthroplasty rather than femoral head arthroplasty to account for the GSD lesions that had accumulated in the acetabulum. To restore the normal walking function of the lower limbs, we performed complete excision of the necrotic tissue followed by total hip arthroplasty. At the 3-year follow-up after surgery, the patient had no pain in the right hip when walking long distances or bearing weight. Radiographs showed that the hip prosthesis was in place and not loose. Moreover, no signs of recurrence were observed in the right hip joint (Figure 4).
Figure 1
Figure 2
Figure 3
Figure 4
Discussion
GSD is a rare benign osteolytic disease characterized by trabecular destruction and resorption of bone, thin-walled capillaries and lymphatic hyperplasia, and the absence of cellular heterogeneity (–). This disease was first reported in 1,838 () and later in 1,872 by Jackson (). Subsequently, Gorham et al. () reviewed 24 cases in the literature and named the disease Gorham-Stout disease in 1955. Although this disease was discovered more than 180 years ago, its etiology and pathogenesis are still unknown. Moreover, there is no clear uniform standard for diagnosis and treatment. In our case, GSD involved the right hip joint, leaving the patient unable to walk. At present, there are very few cases of GSD involving the joints. Cases involving the hip joint and leading to complete dissolution and absorption of the femoral head by nontraumatic causes have rarely been reported.
GSD pathology includes osteoclast activation, angiogenesis and lymphatic angiogenesis caused by cytokines such as TGF-β, PDGF-BB, and VEGF produced by bone macrophages (). T cells participate in the activation of osteoclasts through the RANKL/RANK signaling pathway. In addition, the crosstalk between osteoclasts and T cells through the RANKL/RANKR pathway is also involved in the pathological changes of GSD (). Clinical manifestations, laboratory blood examinations, radiological examinations and histopathological examinations provide strong evidence for the diagnosis of GSD (, , ). Although some cases of GSD are self-limiting and have no symptoms, the majority of cases progress slowly and the symptoms are nonspecific. Therefore, when the diagnosis of GSD is confirmed, massive osteolysis has formed in the involved bone (). Therefore, it may not attract the attention of patients and miss the optimal time for treatment of GSD. Insufficient attention or misdiagnosis can lead to missed optimal treatment opportunities for GSD, which can be life-threatening (). In our case, the patient presented with right hip pain 10 years ago, but the right femoral head had completely disappeared by the time he arrived at our hospital. The results of laboratory blood tests of GSD are usually normal (, ). Relevant blood indicators such as serum calcium, phosphorus, alkaline phosphatase, neutrophil ratio, and leukocyte count can help us exclude bacterial and fungal infections, tuberculosis, metabolic diseases (such as renal osteodystrophy), and endocrine diseases (such as hyperparathyroidism) (, , ). Radiographs are not sensitive enough to identify the early intramedullary or subcortical radiopaque areas in GSD lesion (). When the course of GSD reaches the second stage and beyond, the radiological examination can reveal the bone atrophy, dissolution, and fragmentation of the affected part until the dissolved bone is completely absorbed and replaced by fibrous connective tissue (). In contrast, CT scan, 3D reconstruction and MRI imaging can be more sensitive to detect the intramedullary and subcortical lesions of GSD in the first stage (, ). CT scan and MRI imaging are usually necessary to determine the range of lesions that require surgical removal. ECT and PET/CT are widely recommended as alternative diagnostic examinations because they can assess bone metabolism to determine GSD progression and the effectiveness of treatment (, ). ECT is less costly than PET/CT, but the sensitivity and specificity of ECT in excluding bone tumors and other metabolic diseases are lower than those of PET/CT. Biopsy histopathological examinations are necessary for the diagnosis of GSD in the exclusion of osteosarcoma, metastatic bone tumor, multiple myeloma, and hemangioma.
Medical therapy, radiotherapy, and surgical interventions or combinations are currently available for the treatment of GSD (, , ). Medical therapy is used to prevent or slow the progression of GSD. The current medical therapy includes bisphosphonates, calcium, vitamin D, steroids, procalcitonin, bevacizumab, and interferon-alpha (, –). Among them, bisphosphonates are the most widely used to treat GSD. The pharmacological effects of bisphosphonates include inhibition of osteoclast activity, promotion of osteoclast apoptosis, and inhibition of angiogenesis (, , , ). Local administration has fewer side effects, such as gastrointestinal irritation, osteonecrosis of the jaw, and eye inflammation (, ). It is recommended to combine calcium and vitamin D as essential basic supplements when using bisphosphonates (, ). The course of interferon-alpha treatment for GSD is usually more than 1 year, and it has a wide range of side effects, mainly including blood toxicity, hepatotoxicity and, mental effects (, ). It is necessary to closely monitor blood-related indicators during application. The radiotherapy treatment for GSD is controversial. Radiotherapy of 40–45 Gy at 2 Gy per fraction has been reported to effectively inhibit the activity of osteoclasts (, ). It may have an inhibitory effect on growth in younger patients. Elderly patients may be unable to tolerate radiotherapy and may even develop radiation-induced tumors. Jose R et al. () reported a case of radiotherapy-induced sarcoma in a GSD patient in the left maxilla. Surgical treatment provides the best chance of cure for GSD, especially for patients with massive osteolysis (, , ). Surgical interventions include resection alone, biological reconstruction using autogenous or allogeneic bone after resection and artificial prosthesis reconstruction after resection (, , ). Regardless of the surgical approach, complete removal of the osteolytic lesion is a prerequisite to avoid recurrence of GSD. Considering that the GSD lesion had accumulated in the localized the acetabulum and femoral neck and more complete debridement of diseased tissue, we opted for total hip replacement instead of femoral head arthroplasty. Preoperative use of bisphosphonates to prevent disease progression can help control lesion size (, ). In the literature, GSD patients with joint involvement treated with artificial prostheses have achieved good results with no recurrence (, ). However, there are also risks of loosening, infection, and fractures around the prosthesis. In our case, preoperative use of bisphosphonates to inhibit osteolysis followed by total hip arthroplasty achieved excellent results in restoring hip function.
Conclusion
GSD is a rare benign osteolytic disease, and its etiology and pathogenesis are still unclear. There are no uniform standards for diagnosis and treatment. The combination of clinical manifestations, laboratory examinations, imaging features, and histopathological characteristics is helpful for diagnosis. Medical therapy, radiotherapy, and surgical interventions or combinations are the options for the treatment of GSD. In our case, the combination of bisphosphonates and artificial prosthesis reconstruction achieved good results in the treatment of GSD involving the hip joint, and there was no recurrence at the 3-year follow-up. Medical therapy combined with artificial prosthesis reconstruction may be an effective treatment approach for GSD.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving human participants were reviewed and approved by Medical Ethics Association of the The Second Hospital of Anhui Medical University. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
Conception and design of the research: LZ; Acquisition of data: JL, FY; Analysis and interpretation of the data: YC, SZ; Writing of the manuscript: LZ; Critical revision of the manuscript for intellectual content: HL, JJ. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by the Key Research and Development Program of Anhui Province (No. 202004j07020042).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
YangRHChenPCChangCPWangSJ. Gorham's disease: the disappearing bone. Clin Nucl Med. (2013) 38(5):361–4. 10.1097/RLU.0b013e318286bf93
2.
EllatiRAttiliAHaddadHAl-HussainiMShehadehA. Novel approach of treating gorham-stout disease in the humerus–case report and review of literature. Eur Rev Med Pharmacol Sci. (2016) 20(3):426–32.
3.
BrowneJAShivesTCTrousdaleRT. Thirty-Year follow-up of patient with gorham disease (massive osteolysis) treated with hip arthroplasty. J Arthroplasty. (2011) 26(2):339 e7–10. 10.1016/j.arth.2010.03.003
4.
Franco-BarreraMJZavala-CernaMGAguilar-PortilloGSanchez-GomezDBTorres-BugarinOFranco-BarreraMAet alGorham-Stout disease: a clinical case report and immunological mechanisms in bone erosion. Clin Rev Allergy Immunol. (2017) 52(1):125–32. 10.1007/s12016-016-8594-z
5.
MaillotCClocheTLe HuecJC. Thoracic osteotomy for gorham-stout disease of the spine: a case report and literature review. Eur Spine J. (2018) 27(9):2285–90. 10.1007/s00586-014-3613-3
6.
NikolaouVSChytasDKorresDEfstathopoulosN. Vanishing bone disease (gorham-stout syndrome): a review of a rare entity. World J Orthop. (2014) 5(5):694–8. 10.5312/wjo.v5.i5.694
7.
HuPYuanXGHuXYShenFRWangJA. Gorham-Stout syndrome in mainland China: a case series of 67 patients and review of the literature. J Zhejiang Univ Sci B. (2013) 14(8):729–35. 10.1631/jzus.B1200308
8.
PatelDV. Gorham's disease or massive osteolysis. Clin Med Res. (2005) 3(2):65–74. 10.3121/cmr.3.2.65
9.
SchneiderKNMasthoffMGoshegerGKlingebielSSchornDRoderJet alGorham-Stout disease: good results of bisphosphonate treatment in 6 of 7 patients. Acta Orthop. (2020) 91(2):209–14. 10.1080/17453674.2019.1709716
10.
AgyemanKPretell-MazziniJSubhawongTKerrDAJoseJ. Gorham disease. Am J Orthop (Belle Mead NJ). (2017) 46(6):E458–E62.
11.
ZhengCTangFMinLZhouYLuoYTuCet alGorham-Stout disease of the malleolus: a rare case report. BMC Musculoskelet Disord. (2019) 21(1):3. 10.1186/s12891-019-3027-9
12.
DellingerMTGargNOlsenBR. Viewpoints on vessels and vanishing bones in gorham-stout disease. Bone. (2014) 63:47–52. 10.1016/j.bone.2014.02.011
13.
LudwigKFSloneTCederbergKBSilvaATDellingerM. A new case and review of chylothorax in generalized lymphatic anomaly and gorham-stout disease. Lymphology. (2016) 49(2):73–84.
14.
PatrickJH. Massive osteolysis complicated by chylothorax successfully treated by pleurodesis. J Bone Joint Surg Br. (1976) 58(3):347–9. 10.1302/0301-620X.58B3.956254
15.
TieMLPolandGARosenowECIII. Chylothorax in Gorham's Syndrome. A common complication of a rare disease. Chest. (1994) 105(1):208–13. 10.1378/chest.105.1.208
16.
HeffezLDokuHCCarterBLFeeneyJE. Perspectives on massive osteolysis. Report of a case and review of the literature. Oral Surg Oral Med Oral Pathol. (1983) 55(4):331–43. 10.1016/0030-4220(83)90185-8
17.
JacksonJ. A boneless arm. Boston Med Surg J. (1838) 18:368–9. 10.1056/NEJM183807110182305
18.
JacksonJ. Absorption of the humerus after fracture. Boston Med Surg J. (1872) 87:245–47. 10.1056/NEJM187210100871501
19.
GorhamLWStoutAP. Massive osteolysis (acute spontaneous absorption of bone, phantom bone, disappearing bone); its relation to hemangiomatosis. J Bone Joint Surg Am. (1955) 37-A(5):985–1004. 10.2106/00004623-195537050-00008
20.
LiuYZhongDRZhouPRLvFMaDDXiaWBet alGorham-Stout disease: radiological, histological, and clinical features of 12 cases and review of literature. Clin Rheumatol. (2016) 35(3):813–23. 10.1007/s10067-014-2780-2
21.
SpiethMEGreenspanAForresterDMAnsariANKimuraRLGleason-JordanI. Gorham's disease of the radius: radiographic, scintigraphic, and mri findings with pathologic correlation. A case report and review of the literature. Skeletal Radiol. (1997) 26(11):659–63. 10.1007/s002560050306
22.
ChungCYuJSResnickDVaughanLMHaghighiP. Gorham syndrome of the thorax and cervical spine: ct and mri findings. Skeletal Radiol. (1997) 26(1):55–9. 10.1007/s002560050192
23.
Elera-FitzcarraldCUgarte-GilMF. Gorham-Stout syndrome: a phantom bone disease treated with bisphosphonates. J Clin Rheumatol. (2020) 26(5):e135–e6. 10.1097/RHU.0000000000001009
24.
AizawaTSatoTKokubunS. Gorham disease of the spine: a case report and treatment strategies for this enigmatic bone disease. Tohoku J Exp Med. (2005) 205(2):187–96. 10.1620/tjem.205.187
25.
HagbergHLambergKAstromG. Alpha-2b interferon and oral clodronate for Gorham's Disease. Lancet. (1997) 350(9094):1822–3. 10.1016/S0140-6736(05)63639-2
26.
HammerFKennWWesselmannUHofbauerLCDellingGAllolioBet alGorham-Stout disease–stabilization during bisphosphonate treatment. J Bone Miner Res. (2005) 20(2):350–3. 10.1359/JBMR.041113
27.
RadhakrishnanKRocksonSG. Gorham's disease: an osseous disease of lymphangiogenesis?Ann N Y Acad Sci. (2008) 1131:203–5. 10.1196/annals.1413.022
28.
TakahashiAOgawaCKanazawaTWatanabeHSuzukiMSuzukiNet alRemission induced by interferon alfa in a patient with massive osteolysis and extension of lymph-hemangiomatosis: a severe case of gorham-stout syndrome. J Pediatr Surg. (2005) 40(3):E47–50. 10.1016/j.jpedsurg.2004.11.015
29.
DunbarSFRosenbergAMankinHRosenthalDSuitHD. Gorham's massive osteolysis: the role of radiation therapy and a review of the literature. Int J Radiat Oncol*Biol*Physics. (1993) 26(3):491–7. 10.1016/0360-3016(93)90968-2
30.
HeydRMickeOSurholtCBergerBMartiniCFullerJet alRadiation therapy for gorham-stout syndrome: results of a national patterns-of-care study and literature review. Int J Radiat Oncol Biol Phys. (2011) 81(3):e179–85. 10.1016/j.ijrobp.2011.01.006
31.
Rodriguez-VazquezJRChandraSRAlbertsonMEHansenNJJohnsonCM. Radiation-Induced sarcoma on 18f-fdg pet/ct after treatment of gorham-stout disease of the maxilla. Clin Nucl Med. (2019) 44(11):e607–e8. 10.1097/RLU.0000000000002761
32.
FengLWuYYuXZhaoW. Gorham's disease: treatment with an autologous iliac bone graft and a reverse total shoulder arthroplasty. BMC Musculoskelet Disord. (2019) 20(1):73. 10.1186/s12891-019-2436-0
Summary
Keywords
gorham-Stout disease, bisphosphonates, arthroplasty, hip joint, histopathological, radiological features
Citation
Zhang L, Li J, Yao F, Chen Y, Zhang S, Lv H and Jing J (2023) Treatment of gorham-stout disease with bisphosphonates and total hip arthroplasty: A case report. Front. Surg. 10:1078869. doi: 10.3389/fsurg.2023.1078869
Received
24 October 2022
Accepted
11 January 2023
Published
30 January 2023
Volume
10 - 2023
Edited by
Qiling Yuan, Xi'an Jiaotong University, China
Reviewed by
Fanxiao Liu, Shandong Provincial Hospital, China Osvaldo Mazza, University Hospital Pediatric Department, Italy
Updates
Copyright
© 2023 Zhang, Li, Yao, Chen, Zhang, Lv and Jing.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hao Lv pefloxaciner@126.com JueHua Jing jjhhu@sina.com
These authors have contributed equally to this work and share first authorship
Specialty Section: This article was submitted to Orthopedic Surgery, a section of the journal Frontiers in Surgery
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.